A synthetic progestogen
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Drospirenone

Item No. 23347

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1,3',4',6R,7R,8R,9S,10R,11,12,13S,14S,15S,16S,20,21-hexadecahydro-10,13-dimethyl-spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'S(5'H)-furan]-3,5'(2H)-dione
CAS Number
67392-87-4
Synonyms
  • 1,2-dihydro Spirorenone
  • ZK 30595
Molecular Formula
C24H30O3
Formula Weight
366.5
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 2 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/ml
λmax
259 nm
SMILES
O=C(CC1)O[C@@]21[C@@H](C3)[C@@H]3[C@@]4([H])[C@]5([H])[C@@H]6[C@@H](C6)C7=CC(CC[C@]7(C)[C@@]5([H])CC[C@@]42C)=O
InChi Code
InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
InChi Key
METQSPRSQINEEU-HXCATZOESA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $60

    Add

    50 mg

    $255

    Add

    100 mg

    $393

    Add

    250 mg

    $842

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Drospirenone is a synthetic progestogen that binds to the progesterone, mineralocorticoid, and androgen receptors with binding affinities of 20, 230, and 65% relative to R5020, aldosterone (Item No. 15273), and R1881, respectively.1 In vivo, drospirenone inhibits spontaneous ovulation in rats (ID50s = 0.3-1.0 mg/day) when administered orally or subcutaneously.2 Drospirenone (0.5 mg/animal) administered six times per day maintains pregnancy in ovariectomized pregnant rats. It reduces serum testosterone (Item Nos. 15645 | ISO60154) and luteinizing hormone in cynomolgus monkeys in a dose-dependent manner. Drospirenone (10 mg/animal per day) also inhibits testosterone-induced growth of the seminal vesicles and prostate in castrated rats. Formulations containing drospirenone have been used as oral contraceptives.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Pollow, K., Juchem, M., Elger, W., et al. Dihydrospirorenone (ZK30595): A novel synthetic progestagen - characterization of binding to different receptor proteins. Contraception 46(6), 561-574 (1992).

    2. Muhn, P., Fuhrmann, U., Fritzemeier, K.-H., et al. Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann. N. Y. Acad. Sci. 761(1), 311-335 (1995).

    3. Apter, D., Zimmerman, Y., Beekman, L., et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: Results from a phase II, randomised, dose-finding study (FIESTA). Contraception 94(4), 366-373 (2016).